Predict your next investment

Venture Capital
emvllp.com/biographies.html

See what CB Insights has to offer

Investments

7

Portfolio Exits

2

About Thomas Fogarty

Thomas J. Fogarty is an angel investor, venture capitalist and cardiovascular surgeon by training. He is the managing director at EMV Partners as well as a co-founder and Managing Director at Emergent Medical Ventures. Dr Fogarty is a serial entrepreneur who founded Novare Surgical Systems in 1999 and prior to that, he co-founded General Surgical Innovations. In addition, he has founded or co-founded Arbor Surgical Technologies and Vascular Architects. He is also the co-founder of Satiety.

Thomas Fogarty Headquarter Location

3283 Alpine Road

Portola Valley, California, 94028,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Thomas Fogarty News

Ra Medical Systems Appoints Thomas Fogarty as Chief Commercial Officer

Dec 17, 2018

December 17, 2018 08:00 AM Eastern Standard Time CARLSBAD, Calif.--( BUSINESS WIRE )-- Ra Medical Systems, Inc. (NYSE: RMED) hires Thomas Fogarty as Chief Commercial Officer, effectively immediately. Mr. Fogarty brings over two decades of medical device leadership and commercialization experience to Ra Medical Systems and will oversee all aspects of the Company's commercialization efforts, which include the sales and marketing of its proprietary excimer laser systems that treat tough vascular and dermatological diseases. “Over the years, Tom has demonstrated a proven track record leading both early-stage companies and large corporations through commercialization and sales growth,” said Dean Irwin, Chief Executive Officer, Ra Medical Systems. “These unique characteristics make him the right fit to lead Ra Medical’s commercial efforts at such a pivotal time for our Company. I believe that Tom’s results-oriented leadership approach and proven ability to ramp up sales will ultimately drive Ra Medical to the forefront of life-saving innovation as we continue to roll out our DABRA catheter and laser system around the world.” Mr. Fogarty joins Ra Medical Systems from Neurvana Medical, LLC, where he served as President and Chief Executive Officer. Over the years, Mr. Fogarty also worked at Alliance HealthCare Services Inc., Bioness, Inc. and ev3, Inc. (now Medtronic) in various executive, sales and marketing roles. Earlier in Mr. Fogarty’s career, he held sales and marketing positions at Medtronic, Baxter and Johnson & Johnson. At Bioness, Mr. Fogarty brought four new products to market and significantly increased sales over three years. At ev3, Inc., Mr. Fogarty was responsible for the development and leadership of the global commercial effort, including the launch and sales growth of several products. “Joining the Ra Medical team will allow me to leverage my global commercialization experience to boost Ra Medical’s sales and further expand the Company’s commercial efforts,” added Mr. Fogarty. “Having the opportunity to work with a dedicated management team to further this powerful mission of saving lives and limbs is a once-in-a-lifetime opportunity.” Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical's future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern Ra Medical's future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential expansion of Ra Medical’s business, including the continued rollout of the DABRA catheter and laser system across the U.S. and internationally. Ra Medical's expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of DABRA and Pharos and procedures performed using such devices by physicians, payors, and other third parties; development and acceptance of new products or product enhancements; clinical and statistical verification of the benefits achieved via the use of Ra Medical’s products; the Company’s ability to effectually manage inventory; Ra Medical’s ability to recruit and retain management and key personnel; Ra Medical’s need to comply with complex and evolving laws and regulations; intense and increasing competition and consolidation in Ra Medical’s industry; the impact of rapid technological change; costs and adverse results in any ongoing or future legal proceedings; adverse outcome of regulatory inspections; and the other risks and uncertainties described in Ra Medical’s news releases and filings with the Securities and Exchange Commission. Information on these and additional risks, uncertainties, and other information affecting Ra Medical's business and operating results is contained in Ra Medical’s final prospectus relating to its initial public offering and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law. Ra Medical investors and others should note that we announce material information to the public about the Company through a variety of means, including our website ( www.ramed.com ), our investor relations website ( https://ir.ramed.com/ ), press releases, SEC filings, and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time. About Ra Medical Systems Ra Medical Systems was founded in 2002 and is a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of dermatologic and vascular diseases. DABRA, launched in 2017, is used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. DABRA quickly, photochemically dissolves plaque to the components of its fundamental chemistry. Pharos launched in 2004 and is used as a tool in the treatment of dermatological skin disorders, including psoriasis and vitiligo.

Thomas Fogarty Investments

7 Investments

Thomas Fogarty has made 7 investments. Their latest investment was in Novasom as part of their Series D on June 6, 2011.

CBI Logo

Thomas Fogarty Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/29/2011

Series D

Novasom

$35M

No

1

3/15/2011

Series D

Subscribe to see more

$99M

Subscribe to see more

0

9/14/2009

Series E

Subscribe to see more

$99M

Subscribe to see more

0

5/22/2009

Debt

Subscribe to see more

$99M

Subscribe to see more

0

1/9/2009

Series C

Subscribe to see more

$99M

Subscribe to see more

0

Date

6/29/2011

3/15/2011

9/14/2009

5/22/2009

1/9/2009

Round

Series D

Series D

Series E

Debt

Series C

Company

Novasom

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$35M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

0

0

0

0

Thomas Fogarty Portfolio Exits

2 Portfolio Exits

Thomas Fogarty has 2 portfolio exits. Their latest portfolio exit was Novasom on August 14, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/14/2019

Asset Sale

$99M

1

12/4/2012

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/14/2019

12/4/2012

Exit

Asset Sale

Acquired

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

1

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.